Newly diagnosed PAH patients on triple therapy have fewer hospitalizations vs. double therapy

Feb 18, 2025

1 min read

A study looked at about 3000 pulmonary arterial hypertension patients and found that people who added selexipag to double therapy (an endothelin receptor agonist like ambrisentan, macitentan, or bosentan and a phosphodiesterase type 5 inhibitor like sildenafil or tadalafil) within six months had a lower risk of hospitalization and disease progression. They suggest that delaying the start of triple therapy contributes to worse outcomes.

Read the JAMA Network Open paper

Recent Posts

Frequent imaging of children with PH may lead to high radiation doses

A 41-study review of children with non-cancer chronic diseases looked at how much radiation they were exposed to during their relatively frequent medical imaging. Children with PH were included. The r

What affects physical activity for people with PH?

A UK study examined the factors that affected physical activity participation among people with pulmonary hypertension (PH). They found four themes: fear of breathlessness; lack of motivation and a de

Why men with systemic sclerosis-associated PAH fare worse

Men with systemic sclerosis and pulmonary arterial hypertension (PAH) tend to have more heart-related complications and lower survival rates. Differences in the effects of hormones such as estrogen an

Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.